# Hematologic Malignancies

> **NIH NIH P30** · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · 2022 · $56,942

## Abstract

Hematologic Malignancies Program
ABSTRACT
The goal of the Hematologic Malignancies (HM) Program is to improve outcomes and expand opportunities for
patients with leukemia, Hodgkin and non-Hodgkin lymphoma, and multiple myeloma by integrating basic,
translational, and clinical research through close collaborations among investigators in the Program. Research
collaborations are facilitated through disease- and modality-specific research teams that meet regularly,
including leukemia, lymphoma, multiple myeloma, transplant, immunotherapy, and gene therapy. Each of these
teams works in an integrated manner and includes multi-disciplinary collaborators from the HM Program as well
as from other Cancer Center programs and cores.
The Themes of our program are the following:
Theme 1: Identify key biological pathways and targeting strategies for hematologic malignancies.
Theme 2: Develop novel therapeutic approaches for early-phase clinical testing.
Theme 3: Advance translational research in hematopoietic cell transplantation (HCT) and adoptive
 cellular immunotherapy (ACIT).
The HM Program improves public health both through its refinement of currently available treatment options for
hematological malignancies and its advancement of novel therapies to the clinic, via an intensive Phase I/II
investigational drug program. We are exploring multiple avenues of treatment – chemotherapy, immunotherapy,
gene therapy, targeted therapy, chimeric antigen receptor T cell therapy and HCT – to improve patient cure rates
and treatment tolerability throughout the disease course.
Membership: 37 Program Members representing 8 basic and clinical departments
Publications: 319 total. 29.2% intra-programmatic; 35.1% inter-programmatic; 45.5% inter-institutional
Funding: $6,409,859 peer-reviewed; $3,670,074 of which is NCI funding

## Key facts

- **NIH application ID:** 10328532
- **Project number:** 5P30CA033572-39
- **Recipient organization:** BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
- **Principal Investigator:** Stephen J Forman
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $56,942
- **Award type:** 5
- **Project period:** 1997-08-01 → 2023-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10328532

## Citation

> US National Institutes of Health, RePORTER application 10328532, Hematologic Malignancies (5P30CA033572-39). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10328532. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*